KUALA LUMPUR: CIMB Equities Research has started coverage of Pharmaniaga
with an Add rating and target price of RM6.50, which is 51.2% above the last traded price of RM4.30.
It said on Thursday its target price of RM6.50 was based on 19.2 times CY15 price-to-earnings (P/E), a 20% premium over its three-year average forward P/E in view of its strong earnings per share (EPS) compounded annual growth rate (CAGR) of 28.1% for FY13-16.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
